Methods of screening for compounds which bind G...

Details Methods of screening for compounds which bind G... Methods of screening for compounds which bind G...

2011-04-19

2011-04-19

Landsman, Robert (Department: 1647)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S007210, C436S501000, C530S350000

Reexamination Certificate

active

07927821

ABSTRACT:
The present invention provides a method of screening an agonist or antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using the receptor protein or a salt thereof and the ligand or a salt thereof; etc. The present invention is useful for screening agents for the prevention/treatment of, e.g., leukopenia, leukemia, lymphoma, malignant tumor, ulcerative colitis, rheumatoid arthritis, inflammatory bowel disorders, tonsil disorders, collagen disease, inflammatory disease, leukocytosis, heart failure, inherited muscle disorders, muscular dystrophy, neuromuscular degenerative disease, myocardial infarction, obesity, mellitus diabetes, hyperlipemia, arteriosclerosis, metabolic syndrome, thrombocytopenia, thrombocytosis, cancer, pulmonary edema, multiple organ failure, etc.

REFERENCES:
patent: 5760068 (1998-06-01), Talley et al.
patent: 2002/0103359 (2002-08-01), Donoho et al.
patent: 1477806 (2004-11-01), None
patent: 2002-345491 (2002-12-01), None
patent: WO 01/42287 (2001-06-01), None
patent: WO 01/86305 (2001-11-01), None
patent: WO-03/049727 (2003-06-01), None
patent: WO-03/071272 (2003-08-01), None
patent: WO 2004/063748 (2004-07-01), None
patent: WO2004063748 (2004-07-01), None
patent: WO-2005/023232 (2005-03-01), None
Barry P. Sleckman, et al., “Cloning and Functinal Characterization of the Early-Lymphocyte-Specific Pb99 Gene” ; Molecular and Cellular Biology, Jun. 2000, p. 4405-4410.
Audrey L. Holdebrandt et al., “Antiobesity Effects of Chronic Cannabinoid CB1Receptor Antagonist Treatment in Diet-Induced Obese Mice”; European Journal of Pharmacology 462 (2003) pp. 125-132.
Roger G. Pertwee, “Inverse Agonism and Neutral Antagonism at Cannabinoid CB1Receptors”, Life Sciences 76 (2005) pp. 1307-1324.
David Sugden: “Comparison of the Structure-Activity Relationships of Melatonin Receptor Agonists and Antagonists: Lengthening the N-acyl Side-Chain has Differing Effects on Potency on Xenopus Melaphores”, Naunyn-Schmiedeberg's Arch Pharmacol (1998) 358: pp. 522-528.
International Search Report and Written Opinion for PCT Application PCT/JP2005/007354.
Supplementary European Search Report dated Feb. 11, 2008 for corresponding application EP 05730037.8.
Jones, S. et al., “Cannabinoid receptor systems: therapeutic targets for tumour intervention”, Expert Opin. Ther. Targets (2003) 7(6), pp. 749-758.
McKallip, R.J. et al., “Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease”, Blood (2002), vol. 100, No. 2, pp. 627-634.
Islam, T.C. et al., “High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma”, Leukemia (2003) 17, 1880-1890.
European Office Action dated Jun. 10, 2010, from corresponding European Patent Application No. 05 730 037.8.

Affiliated with

Also associated with

Rating

Methods of screening for compounds which bind G... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of screening for compounds which bind G..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of screening for compounds which bind G... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2701981